SCHEMBL1559244

SCHEMBL1559244

CC(C)(C#N)c1ccc(-c2n[nH]c3cnc4ccc(-c5cncc(N)c5)cc4c23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK2 P49760 9/20 0.43
▸ CLK3 P49761 9/20 0.43
▸ DYRK1A Q13627 9/20 0.43
▸ MTOR P42345 7/20 0.41
▸ PIK3CD O00329 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ PDPK1 O15530 1/20 0.38
▸ PIK3C2A O00443 1/20 0.38
▸ PIK3C2B O00750 1/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ MET P08581 1/20 0.38
▸ PIK3R1 P27986 1/20 0.38
▸ LTK P29376 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ CDK7 P50613 1/20 0.38
▸ NEK2 P51955 1/20 0.38
▸ JAK3 P52333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1559874 0.89 PDPK1 (0.45) MTORPIK3CDPIK3CAPDPK1PIK3C2A
SCHEMBL12266421 0.89 MTOR (0.42) MTORPIK3CDPIK3CAPDPK1PIK3C2A
SCHEMBL2396054 0.89 MAP4K4 (0.46) MTORPIK3CDPIK3CAPDPK1PIK3C2A
SCHEMBL1558604 0.88 PDPK1 (0.41) CLK2CLK3DYRK1AMTORPIK3CD
SCHEMBL2393929 0.87 CLK2 (0.42) CLK2CLK3DYRK1AMTORPIK3CD
SCHEMBL1558861 0.86 MTOR (0.54) MTORPIK3CDPIK3CAPDPK1PIK3C2A
SCHEMBL1557499 0.86 MKNK1 (0.44) CLK2CLK3DYRK1AMTORPIK3CD
SCHEMBL2399164 0.85 MTOR (0.43) MTORPIK3CDPIK3CAPDPK1PIK3C2A
SCHEMBL1557389 0.85 PDPK1 (0.45) CLK2CLK3DYRK1AMTORPIK3CD
SCHEMBL1559173 0.85 MTOR (0.42) MTORPIK3CDPIK3CAPDPK1PIK3C2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
EP-2303890-A2 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS Progenics Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
WO-2009155527-A9 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. (US) 2010-05-06 — — WO disclosed
WO-2009155527-A2 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PIK3CA, AKT1, PIK3R5 CLK2 408/4885CLK3 506/4885DYRK1A 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback